- Trials with a EudraCT protocol (115)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
115 result(s) found for: Glioblastoma Multiforme.
Displaying page 1 of 6.
EudraCT Number: 2009-018258-43 | Sponsor Protocol Number: 327/09 | Start Date*: 2009-09-16 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: SIB-GBM trial (Simultaneous Integrated Boost in Glioblastoma multiforme: hyprofractionated radiotherapy with concomitant boost and temozolomide, in glioblastoma RPA III and IV patients | |||||||||||||
Medical condition: patients affected by glioblastoma multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001664-50 | Sponsor Protocol Number: DS/04/FTMS/01 | Start Date*: 2005-02-04 | |||||||||||
Sponsor Name:ITALFARMACO | |||||||||||||
Full Title: An open label, phase II multicentre evaluation of the activity and safety of fotemustine administered to patients with recurrent or progressive glioblastoma multiforme. | |||||||||||||
Medical condition: Recurrent or progressive glioblastoma multiforme after radiotherapy and adjuvant chemiotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001763-11 | Sponsor Protocol Number: STUDIO GLIMESOR ASL608LIOM02 | Start Date*: 2008-07-09 | ||||||||||||||||
Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST | ||||||||||||||||||
Full Title: LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF TH... | ||||||||||||||||||
Medical condition: PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004138-42 | Sponsor Protocol Number: CLP1000080 | Start Date*: 2006-01-23 | |||||||||||
Sponsor Name:BRAINSGATE LTD | |||||||||||||
Full Title: A multicenter prospective study Safety and feasibility of NeuropathTM Activation during chemiotherapy on Inoperable and Recurrent Glioblastoma Multiforme Patients | |||||||||||||
Medical condition: Recurrent Glioblastoam multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021407-24 | Sponsor Protocol Number: BIBF1120-GBM | Start Date*: 2010-11-09 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Phase II study of BIBF 1120 in recurrent Glioblastoma multiforme | |||||||||||||
Medical condition: Relapsed glioblastoma multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013662-33 | Sponsor Protocol Number: GICNO 08.001 | Start Date*: 2009-12-04 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: PROSPECTIVE EVALUATION OF SERUM MALDI TOF MS PROTEOMIC PROFILE PREDICTIVE OF OUTCOME IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH STANDARD TREATMENT STRATIFIED ACCORDING TO MGMT | |||||||||||||
Medical condition: patients affected by GBM | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003545-11 | Sponsor Protocol Number: DNOG-LOBE-01 | Start Date*: 2020-12-16 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma. | |||||||||||||
Medical condition: recurrent glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018228-14 | Sponsor Protocol Number: S52111 | Start Date*: 2011-07-14 | ||||||||||||||||
Sponsor Name:University Hospital Leuven | ||||||||||||||||||
Full Title: HGG-2010. AS phase IIb prospective placebo-controlled double blind randomized clinical trial for the treatment of patients with newly diagnosed glioblastoma multiforme with tumor vaccination as "ad... | ||||||||||||||||||
Medical condition: Patients with newly diagnosed glioblastoma which can be resected up to a (sub)total extent. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-000700-38 | Sponsor Protocol Number: TEM-LT | Start Date*: 2021-07-12 | ||||||||||||||||
Sponsor Name:GENENTA SCIENCE SRL | ||||||||||||||||||
Full Title: A follow-up study evaluating the long term safety of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-a2 gene... | ||||||||||||||||||
Medical condition: Glioblastoma multiforme (GBM) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001980-41 | Sponsor Protocol Number: CSTI571BDE66 | Start Date*: 2007-02-09 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II s... | |||||||||||||
Medical condition: Glioblastoma multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001104-21 | Sponsor Protocol Number: ND-05006 | Start Date*: 2009-01-28 | |||||||||||
Sponsor Name:VU Cancer Centre, Afdeling Geneeskundige Oncologie | |||||||||||||
Full Title: A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME | |||||||||||||
Medical condition: Recurrent Glioblastoma Multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000572-33 | Sponsor Protocol Number: ParvOryx01 | Start Date*: 2011-09-02 | |||||||||||
Sponsor Name:Oryx GmbH und Co. KG | |||||||||||||
Full Title: Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of PArvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme | |||||||||||||
Medical condition: Glioblastoma multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003679-40 | Sponsor Protocol Number: BEV-CCI-779-GBM-02 | Start Date*: 2008-09-03 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: A phase II study of temsirolimus and bevacizumab in recurrent glioblastoma multiforme | |||||||||||||
Medical condition: Glioblastoma multiforme and progression after prior VEGF-directed therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001144-39 | Sponsor Protocol Number: GBMBIBT01 | Start Date*: 2008-08-12 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: A randomized phase II trial with bevacizumab, irinotecan and cerebral radiotherapy versus bevacizumab, temozolomide and cerebral radiotherapy as first line treatment for patients with glioblastoma ... | |||||||||||||
Medical condition: This study investigates first line experimental non-surgical therapy in patients with glioblastoma multiforme in good performance status | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009879-35 | Sponsor Protocol Number: DEND/GM | Start Date*: 2009-09-03 | |||||||||||
Sponsor Name:Instituto Científico y Tecnológico de Navarra, S.A. | |||||||||||||
Full Title: Estudio prospectivo en fase II de la eficacia y seguridad de la vacunación con células dendríticas autólogas en pacientes con glioblastoma multiforme tras resección quirúrgica completa con microsco... | |||||||||||||
Medical condition: Tratamiento de pacientes con glioblastoma multiforme con células dendríticas autólogas, tras resección quirúrgica completa con microscopio de fluorescencia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001988-75 | Sponsor Protocol Number: RACTAC | Start Date*: 2019-10-22 | |||||||||||
Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | |||||||||||||
Full Title: REPURPOSING THE ANTIPSYCHOTIC DRUG CLORPROMAZINE AS A THERAPEUTIC AGENT IN THE COMBINED TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME | |||||||||||||
Medical condition: Newly diagnosed Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003127-41 | Sponsor Protocol Number: BT009E | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:INSIGHTEC | |||||||||||||
Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) with Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carbopla... | |||||||||||||
Medical condition: Recurrent Glioblastoma (rGBM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015979-27 | Sponsor Protocol Number: TRX2 | Start Date*: 2010-02-25 | |||||||||||
Sponsor Name:Activartis Biotech GmbH | |||||||||||||
Full Title: First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells | |||||||||||||
Medical condition: Patients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiati... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004344-78 | Sponsor Protocol Number: EMD121974-011 | Start Date*: 2008-08-28 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination wi... | |||||||||||||
Medical condition: Newly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter status | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) SK (Completed) HU (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002417-21 | Sponsor Protocol Number: AK2016-2 | Start Date*: 2016-09-22 | ||||||||||||||||
Sponsor Name:Rigshospitalet | ||||||||||||||||||
Full Title: uPAR-PET/MR in glioma | ||||||||||||||||||
Medical condition: Gliomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
